Evidence map›Paper›PMID 25380981›Full record

ArticlePharmaceutical research2015

Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates.

Tsuyoshi Karibe, Rie Hagihara-Nakagomi, Koji Abe, Tomoki Imaoka, Tsuyoshi Mikkaichi, Satoru Yasuda, Masakazu Hirouchi, Nobuaki Watanabe, Noriko Okudaira, Takashi Izumi

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Impact ofJournal of ginseng research · 2019
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Tsuyoshi KaribeDrug Metabolism & Pharmacokinetics Research Laboratories, R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58, Hiromachi, Shinagawa-ku, Tokyo, 140-8710, Japan, karibe.tsuyoshi.jn@daiichisankyo.co.jp.
Rie Hagihara-Nakagomi
Koji Abe
Tomoki Imaoka
Tsuyoshi Mikkaichi
Satoru Yasuda
Masakazu Hirouchi
Nobuaki Watanabe
Noriko Okudaira
Takashi Izumi
Daiichi Sankyo (Germany) · DEDaiichi-Sankyo (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate whether the impact of functional modulation of the breast cancer resistance protein (BCRP, ABCG2 421C>A) on human pharmacokinetics after oral administration is predictable using Bcrp knockout mice and cynomolgus monkeys pretreated with a BCRP inhibitor, elacridar.

methodsThe correlation of the changes of the area under the plasma concentration-time curve (AUC) caused by ABCG2 421C>A with those caused by the Bcrp knockout in mice, or BCRP inhibition in monkeys, was investigated using well-known BCRP substrates (rosuvastatin, pitavastatin, fluvastatin, and sulfasalazine).

resultsIn mice, the bioavailability changes, which corrected the effect of systemic clearance by Bcrp knockout, correlated well with the AUC changes in humans, whereas the correlation was weak when AUC changes were directly compared. In monkeys, the AUC changes pretreated with elacridar resulted in a good estimation of those in humans within approximately 2-fold ranges.

conclusionsThis study suggests that pharmacokinetics studies that use the correction of the bioavailability changes in Bcrp knockout mice are effective for estimating clinical AUC changes in ABCG2 421C>A variants for BCRP substrate drugs and those studies in monkeys that use a BCRP inhibitor serve for the assessment of BCRP impact on the gastrointestinal absorption in a non-rodent model.

Indexed as

AcridinesAnimalsAnti-Inflammatory Agents, Non-SteroidalArea Under CurveATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily G, Member 2Caco-2 CellsFatty Acids, MonounsaturatedFemaleFluvastatinHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIndolesIntestinal AbsorptionMacaca fascicularisMaleAbcg2 protein, mouseAcridinesAnti-Inflammatory Agents, Non-SteroidalATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily G, Member 2ElacridarFatty Acids, MonounsaturatedFluvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsIndolespitavastatinQuinolinesRosuvastatin CalciumSulfasalazineTetrahydroisoquinolines

Identifiers

PMID25380981
OpenAlexW1969753954

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.